9 hours ago
Rising Anal Cancer Rates Among People Living With HIV Highlight Urgent Need for Inclusive Screening and Prevention
READ TIME: 3 MIN.
Anal cancer, a disease in which cancerous cells develop in or around the anus, is increasingly recognized as a major health issue for people living with HIV. Studies estimate that the incidence rate of anal cancer among HIV-infected individuals is up to 30 times higher than in the general population, with gay and bisexual men who have sex with men facing the highest risk. HIV-positive women and heterosexual men are also at an elevated risk compared to their HIV-negative peers, underscoring the need for broad, inclusive public health responses .
Most cases of anal cancer are linked to persistent infection with high-risk types of human papillomavirus , particularly HPV16 and HPV18. While most adults encounter HPV at some point, immunosuppression associated with HIV makes it harder for the body to clear the virus, increasing the risk of abnormal cell changes that can lead to cancer .
Gay and bisexual men living with HIV are disproportionately affected by anal cancer. A North American cohort study found anal cancer rates among HIV-infected MSM at 131 per 100,000 person-years, compared to just 2 per 100,000 in HIV-negative men . This disparity is due not only to the higher prevalence of HIV in these populations but also to behavioral and systemic factors, including limited access to preventive screening and stigma surrounding sexual health.
The intersection of HIV and HPV is complex. Both are sexually transmitted, and having one increases the risk of acquiring the other. This produces a cycle where immunosuppression from HIV leads to greater persistence of HPV infection, which in turn increases cancer risk. Despite advances in HIV treatment with highly active antiretroviral therapy , anal cancer rates have plateaued but remain significantly higher in HIV-positive populations .
Early detection is key to successful treatment, yet anal cancer screening remains limited and is not routinely available even in high-risk groups. Most guidelines now recommend regular screening for anal dysplasia and cancer in people living with HIV, but implementation lags behind recommendations .
HPV vaccination is a crucial preventive measure. It is strongly recommended for younger people living with HIV, as it can reduce the risk of developing anal and other HPV-related cancers. Despite its efficacy, vaccine coverage is not universal, partly due to lack of awareness and barriers in healthcare access .
Treatment for anal cancer in HIV-positive individuals generally follows the same protocols as for HIV-negative patients, with concurrent chemotherapy and radiation therapy. Outcomes are similar when patients are on effective HIV treatment, although HIV-positive individuals may experience more acute side effects, such as skin reactions and hematological toxicities. CD4 counts—a measure of immune function—are a critical prognostic factor; higher counts correlate with better treatment outcomes .
LGBTQ+ advocacy organizations stress the importance of affirming, culturally competent healthcare for all people at risk of anal cancer, including transgender people, nonbinary individuals, and cisgender women. Addressing health disparities requires breaking down stigma, improving access to screening, and ensuring that preventive interventions like HPV vaccination reach those most at risk .
Healthcare providers are encouraged to discuss symptoms—such as anal bleeding, pain, lumps, or changes in bowel habits—openly and without judgment. Early evaluation can distinguish between benign conditions and those requiring further investigation .
As the population of people living with HIV ages, persistent disparities in anal cancer rates among LGBTQ+ communities demand coordinated action from public health agencies, medical professionals, and community advocates. Inclusive, stigma-free care and targeted prevention strategies are essential to reducing the burden of anal cancer and promoting health equity.
